Join Growin Stock Community!

Thermo fisher scientific inc(TMO.US AI Earnings Summary)

US StockHealthcare
No presentation for TMO

TMO AI Earnings Summary (In-Depth)

Last updated: 2026-10-21 (US time)

2026 Q3

Core Highlights

  • Stock Price Reaction: Both revenue and earnings beat expectations, and the stock closed higher. THERMO FISHER SCIENTIFIC INC announced its financial results before the U.S. market open on October 21, 2026. Q3 revenue and adjusted EPS both exceeded market expectations, and on earnings day, 10/21, the stock closed at $694.02, up 0.97% from the 10/20 close of $687.37.
  • Market Expectations: Revenue and adjusted EPS for this quarter both surpassed market expectations, with adjusted EPS of $6.68 about 4.4% above the $6.40 TradingView pre-earnings market expectation and revenue of $12.14B about 1.6% above the $11.95B market expectation. The significant earnings beat was primarily driven by profit leverage from strong revenue growth (contributing $0.08), tariff refund recognition (net contribution of $0.15), and favorable foreign exchange movements (contributing $0.03).
  • Against Last Quarter's Guidance: All targets were met and significantly exceeded. Organic revenue growth reached 6%, exceeding last quarter's guidance (4%) by 2.0 percentage points; adjusted EPS of $6.68 was also substantially higher than last quarter's guidance.
  • In One Sentence: Recovery in biotech and pharmaceutical demand drove organic revenue growth to 6% and a full-year outlook raise, and the stock closed up 0.97% on earnings day.

Quarterly Highlights

Adjusted EPS significantly exceeded internal expectations this quarter, primarily driven by the timing of Pharma Services and strong demand for electron microscopes.

  1. Adjusted EPS significantly exceeded expectations: Adjusted EPS for the quarter was $6.68, up 15% year-over-year, and about $0.26 higher than the upper end of the guidance provided last quarter. CFO Jim Meyer broke down the sources of the beat: $0.08 from better-than-expected operational execution (including profit leverage from higher revenue), $0.03 from currency headwinds, and a $0.15 net impact from tariff refunds recognized this quarter.

  2. Organic revenue grew 6%, about 2 percentage points higher than expected: Reported revenue was $12.14B, up 9% year-over-year; organic growth was 6%, higher than the 4% guidance given last quarter. The CFO noted that the organic growth beat was mainly driven by the team's excellent execution, with overall revenue exceeding internal expectations by more than $200M, which also included currency tailwinds.

  3. Laboratory Products and Biopharma Services led the way with 10% organic growth: The segment reported a 15% year-over-year increase in revenue and 10% organic growth, driven by Pharma Services (Patheon business), Research and Safety Market Channels, and Clinical Research businesses. Adjusted operating margin was 15.5%, up 100 basis points year-over-year, benefiting from good productivity and the contribution from the Clario acquisition.

  4. Analytical Instruments segment saw significant margin expansion: Both reported and organic revenue for the Analytical Instruments segment grew 6% year-over-year, and the adjusted operating margin reached 26.9%, up 430 basis points year-over-year, the largest expansion among the four segments. The electron microscopy business benefited from strong demand in semiconductor applications, while chromatography and mass spectrometry businesses also saw good growth.

  5. China returned to low double-digit growth, with strong overall performance in Asia-Pacific: Organic growth in the Asia-Pacific region reached approximately 10%~12% this quarter, and China also reached approximately 10%~12%, mainly driven by the pharmaceutical, biotech, and industrial and applied markets. CFO Jim Meyer pointed out that China's performance was a key contributor to the quarter's beat and continued to improve compared to the previous quarter.

  6. Tariff refunds provided a one-time earnings boost while accelerating strategic investments: The net impact of tariff refunds recognized this quarter was approximately $60M, contributing about 50 basis points to the adjusted operating margin and $0.15 to adjusted EPS. The company simultaneously used part of the refund to accelerate AI deployment, expand Pharma Services capacity, and invest in employees, reflecting a strategic mindset of converting one-time gains into long-term competitiveness.

  7. Full-year free cash flow guidance raised to $7.0B to $7.5B: Year-to-date free cash flow reached $4.6B, with net capital expenditures of $1.2B. The company also completed the sale of its microbiology business, receiving $1.0B in cash, and repaid approximately $1.1B in senior notes, ending the period with $6.1B in cash and short-term investments.

  8. Clario integration progressing smoothly, Accelerator Drug Development strategy continues to win orders: CEO Marc Casper stated that the Clario business is performing well, integration is smooth, and momentum for revenue synergies is building. The Accelerator Drug Development strategy has won a large number of orders in Clinical Research and Pharma Services, covering Phase I to Phase III clinical trials and clinical trial packaging and logistics.

  9. Several high-impact innovative products launched, strengthening market leadership: Key new products this quarter include: Orbitrap Isora mass spectrometer (the first Orbitrap system for isotope ratio analysis), EMPAD G2 electron detector (supporting next-generation semiconductor research), FDA-cleared EliA CTD 13 Screen autoimmune diagnostic reagent, and the Ion 560 chip (nearly doubling sequencing capacity compared to its predecessor).

Sign up for free!

You can sign up for free or Log In to read more information!

Free In-Depth for popular US stocks:

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer